193 related articles for article (PubMed ID: 21647864)
21. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate.
Ruperto N; Murray KJ; Gerloni V; Wulffraat N; de Oliveira SK; Falcini F; Dolezalova P; Alessio M; Burgos-Vargas R; Corona F; Vesely R; Foster H; Davidson J; Zulian F; Asplin L; Baildam E; Consuegra JG; Ozdogan H; Saurenmann R; Joos R; Pistorio A; Woo P; Martini A;
Arthritis Rheum; 2004 Jul; 50(7):2191-201. PubMed ID: 15248217
[TBL] [Abstract][Full Text] [Related]
22. Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids.
Pileggi GS; de Souza CB; Ferriani VP
Arthritis Care Res (Hoboken); 2010 Jul; 62(7):1034-9. PubMed ID: 20235203
[TBL] [Abstract][Full Text] [Related]
23. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.
Doyle MK; Rahman MU; Han C; Han J; Giles J; Bingham CO; Bathon J
Semin Arthritis Rheum; 2009 Oct; 39(2):123-31. PubMed ID: 18823645
[TBL] [Abstract][Full Text] [Related]
24. [Epidemioclinical aspects of dermatomyositis in the region of Tunis].
Khelifa E; Benmously R; Fenniche S; Marrak H; Zghal M; Mokhtar I
Tunis Med; 2007 Aug; 85(8):655-8. PubMed ID: 18254286
[TBL] [Abstract][Full Text] [Related]
25. Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis.
Schmeling H; Stephens S; Goia C; Manlhiot C; Schneider R; Luthra S; Stringer E; Feldman BM
Rheumatology (Oxford); 2011 May; 50(5):885-93. PubMed ID: 21156669
[TBL] [Abstract][Full Text] [Related]
26. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis.
Papsdorf V; Horneff G
Rheumatology (Oxford); 2011 Jan; 50(1):214-21. PubMed ID: 21148155
[TBL] [Abstract][Full Text] [Related]
27. Effect of early treatment in polymyositis and dermatomyositis.
Naji P; Shahram F; Nadji A; Davatchi F
Neurol India; 2010; 58(1):58-61. PubMed ID: 20228465
[TBL] [Abstract][Full Text] [Related]
28. Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy.
Kimball AB; Summers RM; Turner M; Dugan EM; Hicks J; Miller FW; Rider LG
Arthritis Rheum; 2000 Aug; 43(8):1866-73. PubMed ID: 10943878
[TBL] [Abstract][Full Text] [Related]
29. The methotrexate therapeutic response in rheumatoid arthritis.
Ortendahl M; Holmes T; Schettler JD; Fries JF
J Rheumatol; 2002 Oct; 29(10):2084-91. PubMed ID: 12375316
[TBL] [Abstract][Full Text] [Related]
30. Analysis of Published Criteria for Clinically Inactive Disease in a Large Juvenile Dermatomyositis Cohort Shows That Skin Disease Is Underestimated.
Almeida B; Campanilho-Marques R; Arnold K; Pilkington CA; Wedderburn LR; Nistala K;
Arthritis Rheumatol; 2015 Sep; 67(9):2495-502. PubMed ID: 25988361
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
Quartier P; Taupin P; Bourdeaut F; Lemelle I; Pillet P; Bost M; Sibilia J; Koné-Paut I; Gandon-Laloum S; LeBideau M; Bader-Meunier B; Mouy R; Debré M; Landais P; Prieur AM
Arthritis Rheum; 2003 Apr; 48(4):1093-101. PubMed ID: 12687553
[TBL] [Abstract][Full Text] [Related]
32. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis.
Huber AM; Lang B; LeBlanc CM; Birdi N; Bolaria RK; Malleson P; MacNeil I; Momy JA; Avery G; Feldman BM
Arthritis Rheum; 2000 Mar; 43(3):541-9. PubMed ID: 10728746
[TBL] [Abstract][Full Text] [Related]
33. Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool.
Sanner H; Sjaastad I; Flatø B
Rheumatology (Oxford); 2014 Sep; 53(9):1578-85. PubMed ID: 24692575
[TBL] [Abstract][Full Text] [Related]
34. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis.
Silverman E; Spiegel L; Hawkins D; Petty R; Goldsmith D; Schanberg L; Duffy C; Howard P; Strand V
Arthritis Rheum; 2005 Feb; 52(2):554-62. PubMed ID: 15693001
[TBL] [Abstract][Full Text] [Related]
35. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis.
Kimura Y; Pinho P; Walco G; Higgins G; Hummell D; Szer I; Henrickson M; Watcher S; Reiff A
J Rheumatol; 2005 May; 32(5):935-42. PubMed ID: 15868633
[TBL] [Abstract][Full Text] [Related]
36. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients.
Ravelli A; Trail L; Ferrari C; Ruperto N; Pistorio A; Pilkington C; Maillard S; Oliveira SK; Sztajnbok F; Cuttica R; Beltramelli M; Corona F; Katsicas MM; Russo R; Ferriani V; Burgos-Vargas R; Magni-Manzoni S; Solis-Valleoj E; Bandeira M; Zulian F; Baca V; Cortis E; Falcini F; Alessio M; Alpigiani MG; Gerloni V; Saad-Magalhaes C; Podda R; Silva CA; Lepore L; Felici E; Rossi F; Sala E; Martini A
Arthritis Care Res (Hoboken); 2010 Jan; 62(1):63-72. PubMed ID: 20191492
[TBL] [Abstract][Full Text] [Related]
37. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.
Rider LG; Aggarwal R; Pistorio A; Bayat N; Erman B; Feldman BM; Huber AM; Cimaz R; Cuttica RJ; de Oliveira SK; Lindsley CB; Pilkington CA; Punaro M; Ravelli A; Reed AM; Rouster-Stevens K; van Royen-Kerkhof A; Dressler F; Saad Magalhaes C; Constantin T; Davidson JE; Magnusson B; Russo R; Villa L; Rinaldi M; Rockette H; Lachenbruch PA; Miller FW; Vencovsky J; Ruperto N;
Ann Rheum Dis; 2017 May; 76(5):782-791. PubMed ID: 28385804
[TBL] [Abstract][Full Text] [Related]
38. Treatment of pediatric localized scleroderma: results of a survey of North American pediatric rheumatologists.
Li SC; Feldman BM; Higgins GC; Haines KA; Punaro MG; O'Neil KM
J Rheumatol; 2010 Jan; 37(1):175-81. PubMed ID: 19918041
[TBL] [Abstract][Full Text] [Related]
39. Network in pediatric rheumatology: the example of pediatric rheumatology international trials organisation.
Ruperto N; Martini A
Georgian Med News; 2008 Mar; (156):68-74. PubMed ID: 18403813
[TBL] [Abstract][Full Text] [Related]
40. The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the definition of improvement.
Ruperto N; Ravelli A; Oliveira S; Alessio M; Mihaylova D; Pasic S; Cortis E; Apaz M; Burgos-Vargas R; Kanakoudi-Tsakalidou F; Norambuena X; Corona F; Gerloni V; Hagelberg S; Aggarwal A; Dolezalova P; Saad CM; Bae SC; Vesely R; Avcin T; Foster H; Duarte C; Herlin T; Horneff G; Lepore L; van Rossum M; Trail L; Pistorio A; Andersson-Gäre B; Giannini EH; Martini A;
Arthritis Rheum; 2006 Jun; 55(3):355-63. PubMed ID: 16739203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
